Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2023-06-15 Board/Management Inform…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
PR CFO COO Appointment_NL_Final.pdf
Board/Management Information Classification · 99% confidence The document is a press release announcing a significant management change: the appointment of Thad Huston as CFO and COO, effective July 1, 2023. It details his background and includes standard forward-looking statements and contact information typical of corporate announcements. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2023-06-15 Dutch
6-K Filing
Regulatory Filings
2023-06-15 English
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
Board/Management Information Classification · 100% confidence The document is a press release dated June 12, 2023, announcing the appointment of Dr. Susanne Schaffert as a non-executive independent member of the Board of Directors, replacing a resigning member. This content directly relates to changes in the company's board of directors and senior management structure. This aligns perfectly with the definition for Board/Management Information (MANG). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-06-13 Dutch
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
Board/Management Information Classification · 100% confidence The document is a press release dated June 12, 2023, announcing the appointment of Dr. Susanne Schaffert as a non-executive independent Director to the Board of Directors, replacing Dr. Rajesh Parekh. This content directly relates to changes in the company's board of directors and senior management. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific management change.
2023-06-13 English
6-K Filing
Regulatory Filings
2023-06-13 English
6-K Filing
Regulatory Filings
2023-06-12 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.